N
Nassim Kamar
Researcher at Paul Sabatier University
Publications - 696
Citations - 25605
Nassim Kamar is an academic researcher from Paul Sabatier University. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 73, co-authored 628 publications receiving 20442 citations. Previous affiliations of Nassim Kamar include French Institute of Health and Medical Research & Tabriz University of Medical Sciences.
Papers
More filters
Journal ArticleDOI
Effect of FTY720 on apoptosis of smooth muscle cells.
Torsten Böhler,J. Guillebaud,Lucie Etienne,Cindy Canivet,Nassim Kamar,Lionel Rostaing,Jean-Claude Thiers,Sylvain Galvani,Nathalie Augé,Robert Salvayre,Anne Nègre-Salvayre,Mogens Thomsen +11 more
TL;DR: Low doses of FTY720 used in clinics for treatment of renal allografts and multiple sclerosis did not induce SMC apoptosis, and doses higher than 10 micromol/L induced apoptosis after 48 hours incubation.
Journal ArticleDOI
Beneficial effect of conversion to belatacept in kidney-transplant patients with a low glomerular-filtration rate.
Julie Belliere,Céline Guilbeau-Frugier,Arnaud Del Bello,Laure Esposito,Caroline Capuani,Isabelle Cardeau-Desangles,Lionel Rostaing,Nassim Kamar +7 more
TL;DR: These case reports show that belatacept can be used as a rescue therapy, even if kidney function is very low in kidney-transplant patients who cannot tolerate CNIs and/or mTOR inhibitors.
Journal Article
Alteration of direct and indirect effects of cytomegalovirus.
TL;DR: Whereas it has been shown that cytomegalovirus prophylaxis can decrease the direct and indirect effects of the virus, recent data indicate that pre-emptive therapy has no long-term impact upon the indirect effects.
Journal ArticleDOI
Recurrence of oxalate nephropathy after isolated kidney transplantation for primary hyperoxaluria type 2
TL;DR: It is suggested that combined liver–kidney transplantation should be considered for patients with end-stage chronic kidney disease (CKD) caused by primary hyperoxaluria type 2 (PH2), in contrast to isolated kidney transplantation that is usually proposed.
Journal ArticleDOI
Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients
TL;DR: It is concluded that DAAs can be safely used and lead to results in KT candidates and KT patients that are as good as those observed in the nonrenal population.